Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Montelukast in Diabetic Kidney Disease
NCT05362474Phase 3Terminated
- Sponsor
- University of Colorado Denver
- Start
- Jul 2022
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of montelukast in diabetic kidney disease (DKD), sponsored by University of Colorado Denver. Primary endpoint: Change in Albuminuria at 3 months. Started Jul 2022; status: terminated.
02
Drugs
montelukast
03
Conditions
diabetic kidney disease (DKD)
Beyond the preview
Go deeper on NCT05362474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05362474.